These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37268607)

  • 1. Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study.
    Rotem O; Peretz I; Leviov M; Kuchuk I; Itay A; Tokar M; Paluch-Shimon S; Maimon O; Yerushalmi R; Drumea K; Evron E; Sonnenblick A; Gal-Yam E; Goldvaser H; Samih Y; Merose R; Bareket-Samish A; Soussan-Gutman L; Stemmer SM
    NPJ Breast Cancer; 2023 Jun; 9(1):49. PubMed ID: 37268607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy.
    Stemmer SM; Steiner M; Rizel S; Ben-Baruch N; Uziely B; Jakubowski DM; Baron J; Shak S; Soussan-Gutman L; Bareket-Samish A; Fried G; Rosengarten O; Itay A; Nisenbaum B; Katz D; Leviov M; Tokar M; Liebermann N; Geffen DB
    NPJ Breast Cancer; 2019; 5():41. PubMed ID: 31728408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes-exploratory analysis of the Clalit registry.
    Shachar SS; Leviov M; Yerushalmi R; Drumea K; Tokar M; Soussan-Gutman L; Bareket-Samish A; Sonnenblick A; Ben-Baruch N; Evron E; Gal-Yam EN; Paluch-Shimon S; Bar-Sela G; Goldvaser H; Stemmer SM
    NPJ Breast Cancer; 2023 Sep; 9(1):79. PubMed ID: 37775723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
    Poorvu PD; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Collins LC; Peppercorn J; Schapira L; Borges VF; Come SE; Warner E; Jakubowski DM; Russell C; Winer EP; Partridge AH
    J Clin Oncol; 2020 Mar; 38(7):725-733. PubMed ID: 31809240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
    Dieci MV; Guarneri V; Giarratano T; Mion M; Tortora G; De Rossi C; Gori S; Oliani C; Merlini L; Pasini F; Bonciarelli G; Griguolo G; Orvieto E; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P
    Oncologist; 2018 Mar; 23(3):297-305. PubMed ID: 29133514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.
    Stemmer SM; Steiner M; Rizel S; Geffen DB; Nisenbaum B; Peretz T; Soussan-Gutman L; Bareket-Samish A; Isaacs K; Rosengarten O; Fried G; McCullough D; Svedman C; Shak S; Liebermann N; Ben-Baruch N
    NPJ Breast Cancer; 2017; 3():32. PubMed ID: 28900632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry.
    Stemmer SM; Steiner M; Rizel S; Soussan-Gutman L; Ben-Baruch N; Bareket-Samish A; Geffen DB; Nisenbaum B; Isaacs K; Fried G; Rosengarten O; Uziely B; Svedman C; McCullough D; Maddala T; Klang SH; Zidan J; Ryvo L; Kaufman B; Evron E; Karminsky N; Goldberg H; Shak S; Liebermann N
    NPJ Breast Cancer; 2017; 3():33. PubMed ID: 28900633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
    Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
    Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatments and clinical outcomes in stage II colon cancer patients with 12-gene Oncotype DX Colon Recurrence Score® assay-guided therapy: real-world data.
    Brenner B; Shulman K; Hubert A; Man S; Geva R; Ben-Aharon I; Fennig S; Mishaeli M; Yarom N; Bar-Sela G; Brenner R; Shai A; Baehner FL; Russell C; Soussan-Gutman L; Voet H; Bareket-Samish A; Liebermann N
    ESMO Open; 2024 Aug; 9(8):103648. PubMed ID: 39137478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast Cancer.
    Le Du F; Gonzalez-Angulo AM; Park M; Liu DD; Hortobagyi GN; Ueno NT
    Clin Breast Cancer; 2015 Dec; 15(6):458-66. PubMed ID: 26233757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.
    Peethambaram PP; Hoskin TL; Day CN; Goetz MP; Habermann EB; Boughey JC
    NPJ Breast Cancer; 2017; 3():41. PubMed ID: 29067357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of adjuvant chemotherapy in patients with ER + /HER2- breast cancer, assessed by propensity score matching: significance of nuclear grade and nodal status.
    Tanaka N; Hirano A; Hattori A; Ogura K; Kamimura M; Inoue H; Yukawa H; Sakaguchi S; Matsuoka A; Kodera A; Shimizu T
    Breast Cancer; 2021 Jan; 28(1):40-47. PubMed ID: 32592141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21-gene recurrence score: A National Cancer Database analysis.
    Weiser R; Polychronopoulou E; Hatch SS; Haque W; Ghani HA; He J; Kuo YF; Gradishar WJ; Klimberg VS
    Cancer; 2022 May; 128(9):1738-1747. PubMed ID: 35137951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
    Hu G; Hu G; Zhang C; Lin X; Shan M; Yu Y; Lu Y; Niu R; Ye H; Wang C; Xu C
    BMC Cancer; 2020 Feb; 20(1):136. PubMed ID: 32085753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the 21-Gene Recurrence Score Assay in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer and 0 to 3 Positive Lymph Nodes: Risk Pattern and Outcomes on a Community Level.
    Braun M; Kriegmair A; Szeterlak N; Andrulat A; Schrodi S; Kriner M; Hanusch C; Hamann M; Stoetzer O; Pölcher M
    Breast Care (Basel); 2022 Jun; 17(3):288-295. PubMed ID: 35957951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer.
    Bae SJ; Kim JH; Ahn SG; Jeung HC; Sohn J; Kim GM; Kim MH; Kim SI; Park S; Park HS; Kim JY; Jeong J
    Front Oncol; 2021; 11():689587. PubMed ID: 34150658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study.
    Llombart-Cussac A; Anton-Torres A; Rojas B; Andrés R; Martinez N; Rodríguez CA; Marin S; Puértolas T; González AF; Fernández-Murga ML; Hagen C; Ruiz-Borrego M
    Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
    Nguyen TTA; Postlewait LM; Zhang C; Meisel JL; O'Regan R; Badve S; Kalinsky K; Li X
    Breast Cancer Res Treat; 2022 Apr; 192(3):509-516. PubMed ID: 35084624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with late risks of breast cancer-specific mortality in the SEER registry.
    Leone JP; Vallejo CT; Hassett MJ; Leone J; Graham N; Tayob N; Freedman RA; Tolaney SM; Leone BA; Winer EP; Lin NU
    Breast Cancer Res Treat; 2021 Aug; 189(1):203-212. PubMed ID: 33893907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer.
    Constantinidou A; Marcou Y; Toss MS; Simmons T; Bernhisel R; Hughes E; Probst B; Meek S; Kakouri E; Georgiou G; Zouvani I; Savvidou G; Kuhl V; Doedt J; Wagner S; Gutin A; Slavin TP; Lanchbury JS; Kronenwett R; Ellis IO; Rakha EA
    Clin Cancer Res; 2022 Oct; 28(20):4435-4443. PubMed ID: 36043530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.